Similarly, our pharmacological interference with T cell receptor signaling via the calcineurin inhibitor FK506 led to CD4+ T cell lymphopenia with and without EBV infection and compromised immune control of EBV titers as well as associated lymphoproliferative diseases. Here, CD4 is linked to Epstein-Barr virus infection.